Some of our valued sponsors will be hosting symposia during the conference.
Sunday, 7 Nov, 10:00 – 11:00 AM SAST
In this session, we will be delighted to share our vision and initiatives towards a World Without Fear of Cancer. We will speak about our activities in Africa and the solutions we have been designing to bring access to Intelligent Cancer Care. We will also be joined by our users and hear how technology has been helping them offering high quality treatments to their community. We look forward to seeing you in our symposium.
Sunday, 7 Nov, 4:00 PM – 5:30 PM SAST
LEVERAGING EXISTING HIV LABORATORY CAPABILITIES TO TRANSFORM CANCER DIAGNOSIS IN SUB-SAHARAN AFRICA – BECKMAN COULTER SYMPOSIUM
Sunday, 7 Nov, 6:00 PM – 7:15 PM SAST
Leveraging Existing HIV Laboratory Capabilities to Transform Cancer Diagnosis in Sub-Saharan Africa
This educational workshop will be facilitated by Burkitt’s Lymphoma Fund for Africa (BLFA) with focus on improving cancer diagnosis and care in Sub-Saharan Africa. The first part of the workshop will highlight state-of-the art technology that improves speed, accuracy and utility for classifying and diagnosing hematologic malignancies. This section will also emphasize and discuss the importance of measurable residual disease and how this can be applied post-treatment to monitor patients. The second part of the workshop will apply an Oncologist’s perspective on the challenges of bringing patients into care in resource limited settings. This will be an experiential section of the workshop to share lessons from more than a decade of Oncology Care in Western Kenya and how health systems can improve cancer care. The workshop will end with a moderated Q&A taking questions from delegates and answers from the speakers.
BLFA is a nonprofit 501(c)(3) organization based in Seattle, Washington, supporting innovative programs to reduce the disparities in childhood cancer care in underserved areas. Our mission is to cure children with cancer by ensuring patients and families receive the medical, social, and economic support needed to help them successfully access and complete curative treatment. We do this by supporting in-country programs in partnership with NGOs, medical centers, and governmental organizations.
NOVARTIS SCIENTIFIC PRESENTATION (1)
Sunday, 7 Nov, 12:30 PM – 1:45 PM SAST
NOVARTIS SCIENTIFIC PRESENTATION(2)
Monday, 8 Nov, 3:45 PM – 4:45 PM (SAS)
Tuesday, 9 Nov, 11:00 AM – 12:00 PM SAST
Innovations in Women’s Health & Oncology: Using diagnostics to promote
early detection and improved management of cancers affecting women.
ENHANCING SUB-SAHARAN CANCER CARE SYSTEMS FOR TARGETED THERAPY, ONE DEMONSTRATION PROJECT AT A TIME Brought to you by BMSF
Tuesday, November 9, 5:30 PM – 6:30 PM (SAST)
Bristol-Myers Squibb Foundation AORTIC 2021 Workshop Hour: Brief Summary
The Bristol Myers Squibb Foundation Global Cancer Disparities Africa Initiative has a mission to help address cancer disparities with a focus on lung, cervical, paediatric, and multiple myeloma in selected sub-Saharan countries. We value collaboration across the region, focusing on communities most at risk of experiencing disparities to accessing care for serious diseases. We empower our partners to develop and test innovative solutions to advance health equity and improve access to quality healthcare for patients.
We believe the African Organisation for Research and Training in Cancer (AORTIC) Conference provides a good platform for the BMSF Global Cancer Disparities Africa Initiative to create more collaborations, expand our partners’ network and reach, and to learn and share lessons and/or best practices from our interventions with our colleagues across the continent.
Our session, titled “Enhancing Sub-Saharan Cancer Care Systems for Targeted Therapy – One Demonstration Project at a Time”, scheduled for November 9th at 6:30 PM to 7:30 PM SAST, will be inviting cancer experts from Botswana, Tanzania, Geneva, and the United States of America who work closely with cancer institutions on the continent to highlight the importance, relevance, and successes of targeted immuno-therapy in cancer patients in Africa.